Are Analysts Bullish about C. R. Bard, Inc. (NYSE:BCR) after last week?

December 7, 2017 - By Clifton Ray

 Are Analysts Bullish about C. R. Bard, Inc. (NYSE:BCR) after last week?
Investors sentiment decreased to 0.58 in Q2 2017. Its down 0.30, from 0.88 in 2017Q1. It worsened, as 99 investors sold C. R. Bard, Inc. shares while 273 reduced holdings. 103 funds opened positions while 111 raised stakes. 55.14 million shares or 10.97% less from 61.93 million shares in 2017Q1 were reported.
Quantitative Systematic Strategies Ltd Company reported 0.47% in C. R. Bard, Inc. (NYSE:BCR). Comml Bank Of America De has 0.05% invested in C. R. Bard, Inc. (NYSE:BCR). Ameritas Inv Partners owns 2,820 shares. 1.39 million are owned by Northern Trust. Wespac Limited Liability Corp has 2,392 shares for 0.52% of their portfolio. Meeder Asset Mngmt Inc has 0.32% invested in C. R. Bard, Inc. (NYSE:BCR). Manufacturers Life Ins The stated it has 0.03% in C. R. Bard, Inc. (NYSE:BCR). Oak Ltd Oh holds 0.33% or 13,915 shares. Farmers And Merchants holds 0.32% or 12,020 shares. Asset Mgmt One reported 119,257 shares. Aqr Mngmt Ltd Liability holds 0.03% or 60,918 shares in its portfolio. Tiaa Cref Invest Mngmt Limited Company has 257,641 shares for 0.06% of their portfolio. Kentucky Retirement Sys invested 0.11% of its portfolio in C. R. Bard, Inc. (NYSE:BCR). Liberty Mutual Grp Asset Mgmt Inc holds 0.06% in C. R. Bard, Inc. (NYSE:BCR) or 4,646 shares. Peapack Gladstone Fincl holds 0% in C. R. Bard, Inc. (NYSE:BCR) or 3,100 shares.

C. R. Bard, Inc. (NYSE:BCR) Ratings Coverage

Among 15 analysts covering CR Bard (NYSE:BCR), 4 have Buy rating, 0 Sell and 11 Hold. Therefore 27% are positive. CR Bard had 32 analyst reports since August 27, 2015 according to SRatingsIntel. The stock of C. R. Bard, Inc. (NYSE:BCR) has “Sector Weight” rating given on Thursday, August 27 by KeyBanc Capital Markets. The firm has “” rating given on Wednesday, April 26 by Raymond James. The stock of C. R. Bard, Inc. (NYSE:BCR) has “Buy” rating given on Thursday, September 15 by Evercore. The company was maintained on Thursday, June 29 by Jefferies. The firm has “Hold” rating given on Monday, July 10 by BMO Capital Markets. The stock of C. R. Bard, Inc. (NYSE:BCR) earned “Hold” rating by Needham on Friday, September 22. The firm has “Overweight” rating given on Tuesday, January 3 by Morgan Stanley. The company was initiated on Thursday, November 12 by Citigroup. The rating was maintained by Barclays Capital on Wednesday, July 27 with “Equalweight”. The firm has “Strong Buy” rating by Raymond James given on Thursday, January 5. Below is a list of C. R. Bard, Inc. (NYSE:BCR) latest ratings and price target changes.

06/11/2017 Broker: Barclays Capital Rating: Equal-Weight Old Target: $245 New Target: $337 Maintain
11/10/2017 Broker: BMO Capital Markets Rating: Hold New Target: $317.0 Maintain
22/09/2017 Broker: Needham Rating: Hold Maintain
12/09/2017 Broker: Jefferies Rating: Hold New Target: $317.0 Maintain
31/08/2017 Broker: BMO Capital Markets Rating: Hold New Target: $317.0 Maintain
28/07/2017 Broker: Cowen & Co Rating: Hold New Target: $317.0000 Maintain
28/07/2017 Broker: Needham Rating: Hold
10/07/2017 Broker: BMO Capital Markets Rating: Hold New Target: $317.0000 Maintain
29/06/2017 Broker: Jefferies Rating: Hold New Target: $317.0000 Maintain

The stock increased 0.06% or $0.19 during the last trading session, reaching $332.07. About 569,167 shares traded or 16.85% up from the average. C. R. Bard, Inc. (NYSE:BCR) has risen 40.70% since December 7, 2016 and is uptrending. It has outperformed by 24.00% the S&P500.

C. R. Bard, Inc., together with its subsidiaries, designs, makes, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company has market cap of $24.21 billion. The firm offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and a range of minimally invasive devices for the treatment of peripheral vascular and end-stage renal diseases. It has a 43.8 P/E ratio. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems; ureteral stents; specialty devices for stone removal procedures; surgical slings and pelvic floor repair products; catheter stabilization devices; and products for therapeutic hypothermia.

More news for C. R. Bard, Inc. (NYSE:BCR) were recently published by: Investorplace.com, which released: “CR Bard (BCR) a Strong Buy on Exceptional Quant Score” on November 28, 2017. Bizjournals.com‘s article titled: “What Jabil’s new director signals about the company’s future” and published on November 30, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.